CELL REPORTS MEDICINE DOI:10.1016/j.xcrm.2022.100881(2023)

Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases.

一键分享

---